Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group trial (HOT) 0601

Oncology

Volumn 81, Issue 2, 2011, Pages 84-90

  Akie, Kenji ^a   Oizumi, Satoshi ^b   Ogura, Shigeaki ^a   Shinagawa, Naofumi ^b   Kikuchi, Eiki ^b   Fukumoto, Shinichi ^c   Harada, Masao ^c   Kinoshita, Ichiro ^d   Kojima, Tetsuya ^e   Harada, Toshiyuki ^f   Fujita, Yuka ^g   Ohsaki, Yoshinobu ^h   Dosaka Akita, Hirotoshi ^d   Isobe, Hiroshi ^e   Nishimura, Masaharu ^b  

^a SAPPORO CITY GENERAL HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KKR Sapporo Medical Center   (Japan)

^f Hokkaido Social Insurance Hospital   (Japan)

^g National Hospital Organization Asahikawa Medical Center   (Japan)

^h ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Chemotherapy; Irinotecan; Non small cell lung cancer, phase II; Nonplatinum regimens; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HETEROZYGOTE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; TEGAFUR;

EID: 80054947461     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000331681     Document Type: Article

References (30)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
2. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-323. (Pubitemid 46323100)
3. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G: Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a metaanalytical approach. Oncologist 2009;14:497-510.
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Sigenori N, Tetsuo T: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
5. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 1998;78:251-256. (Pubitemid 28302265)
6. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-943. (Pubitemid 33015993)
7. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864. (Pubitemid 39587524)
8. Ozawa Y, Inui N, Naitoh T, Yasuda K, Nagayama M, Shirai T, Suganuma H, Fujii M, Nakamura H, Suda T, Chida K: Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;63:68-71.
9. Tamura K, Okamoto I, Ozaki T, Kashii T, Takeda K, Kobayashi M, Matsui K, Shibata T, Kurata T, Nakagawa K, Fukuoka M: Phase I/ II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Eur J Cancer 2009;45:2132-2137.
10. Kubota K, Sakai H, Yamamoto N, Kunitoh H, Nakagawa K, Takeda K, Ichinose Y, Saijo N, Ariyoshi Y, Fukuoka M: A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:702-706.
11. Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M: Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2010;68:253-257.
12. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K: Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010;28:5240-5246.
13. Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM: Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10:1121-1129. (Pubitemid 38198914)
14. Takiuchi H, Kawabe S, Gotoh M, Katsu K: Thymidylate synthase gene expression in primary tumors predicts activity of s-1- based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 2007;1:171-176.
15. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2006;17:968-973. (Pubitemid 43778988)
16. Komatsu Y, Yuki S, Fuse N, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Sakata Y, Asaka M: Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. Adv Ther 2010;27:483-492.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
18. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B: Role of UG-T1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007;98:1461-1467. (Pubitemid 47241771)
19. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:6921-6926. (Pubitemid 32059164)
20. Yamamoto N, Yamanaka T, Ichinose Y, Kubota K, Sakai H, Gemma A, Saijo N, Fukuoka M, Niitani H: Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res 2010;30:2985-2990.
21. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D: Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-2945. (Pubitemid 46224112)
22. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034. (Pubitemid 46606281)
23. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-2936. (Pubitemid 46224111)
24. Ishimoto O, Ishida T, Honda Y, Munakata M, Sugawara S: Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. Int J Clin Oncol 2009;14:43-47.
25. Okamoto I, Nishimura T, Miyazaki M, Yoshioka H, Kubo A, Takeda K, Ebi N, Sugawara S, Katakami N, Fukuoka M, Nakagawa K: Phase II study of combination therapy with S-1 and irinotecan for advanced nonsmall cell lung cancer: west Japan thoracic oncology group 3505. Clin Cancer Res 2008;14:5250-5254.
26. Atagi S, Kawahara M, Kusunoki Y, Takada M, Kawaguchi T, Okishio K, Kubo A, Uehira K, Yumine K, Tomizawa Y, Saito R, Fukai S, Komatsu H: Phase I/II study of docetaxel and S-1 in patients with previously treated nonsmall cell lung cancer. J Thorac Oncol 2008;3:1012-1017.
27. Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, Yoshioka H, Hayashi H, Kawai H, Aoe K, Maeda T, Ueoka H, Tanimoto M: A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. J Thorac Oncol 2010;5:1430-1434.
28. Satouchi M, Kotani Y, Katakami N, Shimada T, Urata Y, Yoshimura S, Funada Y, Hata A, Ando M, Negoro S: Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naive patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:696-701.
29. Takiguchi Y, Tada Y, Gemma A, Kudoh S, Hino M, Yoshimori K, Yoshimura A, Nagao K, Niitani H: Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 2010;68:409-414.
30. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-860.